Quizartinib advances overall survival in acute myeloid leukaemia patients from flt3 itd mutation positive Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
Description: Dr Harry Erba speaks to ecancer at the EHA 2022 meeting about quizartinib improving the overall survival in adult patients with FLT3-ITD+ acutenmyeloid leukaemia.nn Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults, and approximately 25% of all newly diagnosed cases carry the FLT3-internal tandem duplication (ITD) gene mutation.nnThe results showed that the addition of quizartinib significantly improved overall survival compared with standard induction and consolidation